Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:22:33.671Z.
Consensus retrieved: 2026-10-06T13:36:27.391Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:22:33.671Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 820e6844a86ebcce87b4cbc727545bf8fd5f2e7882f78b89935f6b0fc3bd738c
Forward PE Ratio (N/A) = Dated Quote Price ($2.78) / Consensus Forward EPS ($-1.39)
FORWARD PE RATIO
N/A
Larimar Therapeutics, Inc.
Market Cap
$288.79M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $288.79M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.55M | N/A |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.42M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $292.59M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.31M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $293.30M | N/A |
| Standard BioTools Inc. (LAB)vs › | $282.64M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $271.81M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.78, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.39 | $-1.56 – $-1.31 | 6 | n/m |
| 2027-12-31 | $-1.18 | $-1.50 – $-0.76 | 7 | n/m |
| 2028-12-31 | $-0.53 | $-1.01 – $-0.09 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
